Application of in-house monoclonal antibody resources to a fully retargeted oncolytic herpes simplex virus platform

我们已经报道了一种完全重定向的单纯疱疹病毒(HSV)平台，它结合了单链抗体，专门通过肿瘤相关抗原介导病毒进入。为了进一步发展这个系统，我们成功地利用了我们自己收集的针对人类癌症的单抗。我们的结果表明，我们的系统对不同的靶向配体具有适应性，从而产生了新一代广泛适用和有效的HSV溶瘤载体。

We have reported a fully retargeted herpes simplex virus (HSV) platform that incorporates single-chain antibodies to mediate virus entry exclusively via tumor-associated antigens. For further development of this system, we successfully took advantage of our own collection of monoclonal antibodies directed against human cancers. Our results indicate the adaptability of our system to different targeting ligands, leading to a new generation of broadly applicable and effective oncolytic HSV vectors.